Navigation Links
AtheroNova Receives Notice of Allowance for Its US Patent Application 12/024,908
Date:7/9/2012

technology. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as significant fluctuations in expenses associated with clinical trials, failure to secure additional financing, the inability to complete regulatory filings with the Food and Drug Administration, the introduction of competing products, or management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in AtheroNova's filings with the United States Securities and Exchange Commission. AtheroNova undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE AtheroNova Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. AtheroNova Signs Agreement for Development of Clinical Trial Supplies
2. NeuroSigma Receives Global Quality Control Certification
3. Lifeline Biotechnologies, Inc. Receives Patent Award, a Device for Breast Tissue Temperature Analysis for Determining Cancer Conditions
4. Daiichi Sankyo, Inc. Receives FDA Approval to Package Product at New Facility in Bethlehem, PA
5. China Biologic Receives SFDA Manufacturing Approval Certificate for Human Coagulation Factor VIII
6. Bluechiip Receives First Sales Order from ATCC after Completion of Successful Pilot Trial
7. Surefire Medical Receives FDA Clearance For High-Flow Microcatheter
8. Tetra Discovery Partners Receives Major NIH Award To Develop New Alzheimers Drug
9. Celladon Corporation Receives Notice of Allowance from European Patent Office
10. GSK Receives FDA Approval for MenHibrix®
11. Cardiosolutions, Inc. Receives FDA 510(k) Clearance for Dexterity™ Steerable Introducer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... , Feb. 27, 2015 /CNW/ - Covalon Technologies Ltd. ... technologies company, today announced financial results for its first ... the three months ended December 31, 2014, revenue was ... quarter was $229,820 or $0.02 per share.  ... said "I am very pleased with the significant progress ...
(Date:2/27/2015)... 2015  Organovo Holdings, Inc. (NYSE MKT: ONVO) ... breakthrough 3D bioprinting technology, announced today that ... will present live at VirtualInvestorConferences.com on March 5th. ... us for this Company update," said Mr. Murphy. ... launch of the exVive3D Liver, Bioprinted Human Tissue, ...
(Date:2/27/2015)... MINNEAPOLIS , Feb. 27, 2015  Uroplasty, Inc. (NASDAQ: ... develops, manufactures and markets innovative proprietary products to treat ... the 27th Annual ROTH Conference on Tuesday, March 10, ... Brett Reynolds , Chief Financial Officer, will present ... one on one at the conference at the Ritz ...
Breaking Medicine Technology:Covalon Announces First Quarter Financial Results 2Covalon Announces First Quarter Financial Results 3Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 2Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 3Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 4Uroplasty to Participate in the 27th Annual ROTH Conference 2
... the 2007 ... Chemotherapy Foundation Symposium, BOULDER, Colo., Nov. 9 Pharmion ... Phase 2 trial of,Amrubicin in second-line chemo-sensitive small cell lung ... II inhibitor currently in development for the,treatment of SCLC. These ...
... improvement in disease activity observed through 2.5 years of ... a Phase 2 continuation trial -, - No observed increase ... malignancies and infections over 2.5 years of LymphoStat-B treatment -, ... HGSI ) today announced the presentation of Phase 2 ...
Cached Medicine Technology:Pharmion's Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer 2Pharmion's Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer 3Pharmion's Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer 4Pharmion's Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer 5Human Genome Sciences Reports Positive Data from Long-Term Treatment with LymphoStat-B(R) in Patients with Active Systemic Lupus Erythematosus 2Human Genome Sciences Reports Positive Data from Long-Term Treatment with LymphoStat-B(R) in Patients with Active Systemic Lupus Erythematosus 3Human Genome Sciences Reports Positive Data from Long-Term Treatment with LymphoStat-B(R) in Patients with Active Systemic Lupus Erythematosus 4Human Genome Sciences Reports Positive Data from Long-Term Treatment with LymphoStat-B(R) in Patients with Active Systemic Lupus Erythematosus 5Human Genome Sciences Reports Positive Data from Long-Term Treatment with LymphoStat-B(R) in Patients with Active Systemic Lupus Erythematosus 6Human Genome Sciences Reports Positive Data from Long-Term Treatment with LymphoStat-B(R) in Patients with Active Systemic Lupus Erythematosus 7Human Genome Sciences Reports Positive Data from Long-Term Treatment with LymphoStat-B(R) in Patients with Active Systemic Lupus Erythematosus 8
(Date:3/1/2015)... (PRWEB) March 01, 2015 Theme and ... new transition pack for Final Cut Pro ... accordion style transitions to any FCPX editors project.” Said ... our users the tools needed to easily drag and ... The user gets many different controls over the parameters ...
(Date:2/28/2015)... The MCA Youth Empowerment Conference aims to bridge youths ... towards the goal for a better future for all ... smaller groups will be held after the conference with ... Healthcare, Social and Volunteerism, Women and Youth Empowerment, to ... , Young adults aged between 18-30 years that have ...
(Date:2/28/2015)... Heart diseases are on the rise ... urban adult population and 5 percent of rural adult ... 20-30 percent of them require specialized investigation and treatment ... vascular diseases (CVD). , A division of Indian Business ... report titled “Indian Coronary Stent Market Forecast to 2019”. ...
(Date:2/28/2015)... 2015 Gerald “Solutionman” Haman surveyed over ... barriers to innovative thinking. “The #1 block was ... of tools,” reports Haman, who created the Thinkubator Innovation ... people felt that they did not have enough time ... resources to stimulate innovation. , Solutionman’s monthly “Accelerating Innovation ...
(Date:2/28/2015)... The Heart Fit Clinic started doing ... the machine. The Heart Fit Clinic is also selling ... franchise model. The goal is to scale the business ... To buy External Counterpulsation machines can be ... through this process and achieve the desired results. ...
Breaking Medicine News(10 mins):Health News:Announcing a New Transition Pack from Pixel Film Studios, Transccordion for Final Cut Pro X 2Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 2Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 3Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 4Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 3Health News:New Survey Reveals “Lack of Time” Is the Number #1 Barrier to Innovative Thinking 2Health News:New Survey Reveals “Lack of Time” Is the Number #1 Barrier to Innovative Thinking 3Health News:Clinicians Can Now Purchase External Counterpulsation with Heart Fit Clinic 2
... Offerings to Help Hospitals Prevent Infections, DUBLIN, ... of products and services that improve the safety ... agreement to,acquire the assets of privately held Enturia ... leading line of infection prevention,products sold under the ...
... Organizations Levy Coinsurance, Charges and Other Protocols ... ... Report from Decision Resources, WALTHAM, Mass., March ... and advisory firms for pharmaceutical and,healthcare issues, finds that ...
... Begin Today at 9:00 a.m. ET -, VALENCIA, ... today reported financial results for the fourth,quarter and year ... of 2007, total operating expenses were $79.1,million, compared to ... development (R&D) expenses increased by $7.0 million to $66.8 ...
... March 4 Crdentia Corp. (OTC Bulletin,Board: ... staffing services,today announced the appointment of Mr. ... and Chief Clinical Officer. In this newly ... regulatory compliance and accreditation, assisting in business,plan ...
... 2007 Total Revenue Increased 46.1%, Net Income Rose ... Simcere Pharmaceutical,Group (NYSE: SCR ), a leading ... and supplier of the patented anti-cancer,product Endu in ... ended December 31, 2007 and fiscal year ended ...
... , - Online Resource to Support ... the world-leading publisher of scientific, technical and,medical ... launch of,its Publishing Ethics Resource Kit (PERK),( ... Elsevier Editors, Conference in Singapore, Mark,Seeley, Senior ...
Cached Medicine News:Health News:Cardinal Health Agrees to Acquire ChloraPrep(R) Manufacturer for $490 Million 2Health News:Cardinal Health Agrees to Acquire ChloraPrep(R) Manufacturer for $490 Million 3Health News:Cardinal Health Agrees to Acquire ChloraPrep(R) Manufacturer for $490 Million 4Health News:Cardinal Health Agrees to Acquire ChloraPrep(R) Manufacturer for $490 Million 5Health News:Cardinal Health Agrees to Acquire ChloraPrep(R) Manufacturer for $490 Million 6Health News:Although Remicade and Humira Are Being Increasingly Prescribed for Crohn's Disease and Ulcerative Colitis, Insurers Are Subjecting Both Drugs to Multiple Cost-Control Strategies 2Health News:MannKind Corporation Reports Fourth Quarter and Full Year 2007 Financial Results 2Health News:MannKind Corporation Reports Fourth Quarter and Full Year 2007 Financial Results 3Health News:MannKind Corporation Reports Fourth Quarter and Full Year 2007 Financial Results 4Health News:MannKind Corporation Reports Fourth Quarter and Full Year 2007 Financial Results 5Health News:MannKind Corporation Reports Fourth Quarter and Full Year 2007 Financial Results 6Health News:Crdentia Appoints Randall Turnbull to Senior Vice President and Chief Clinical Officer 2Health News:Crdentia Appoints Randall Turnbull to Senior Vice President and Chief Clinical Officer 3Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2007 Results 2Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2007 Results 3Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2007 Results 4Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2007 Results 5Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2007 Results 6Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2007 Results 7Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2007 Results 8Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2007 Results 9Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2007 Results 10Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2007 Results 11Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2007 Results 12Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2007 Results 13Health News:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2007 Results 14Health News:Elsevier Launches Publishing Ethics Resource Kit 2
The OX-2 is configured asstandalone or handheld unit, designed for hospital, transport and home use....
Rad-9™...
... 8600 Series Tabletop/Portable Digital Pulse ... tool for patient monitering. From ... the 8600 has earned the ... and is recognized for its ...
... Medicals ONE™ technology is the ... uses a patented digital sensor ... an analog sensor. Dolphin ONE™ ... the signal in the sensor, ...
Medicine Products: